DAFNA Capital Management LLC Raises Stock Holdings in Kura Oncology, Inc. $KURA

DAFNA Capital Management LLC raised its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 3.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 463,368 shares of the company’s stock after acquiring an additional 15,000 shares during the period. Kura Oncology makes up approximately 0.9% of DAFNA Capital Management LLC’s holdings, making the stock its 29th biggest holding. DAFNA Capital Management LLC owned approximately 0.54% of Kura Oncology worth $3,058,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Magnetar Financial LLC bought a new position in shares of Kura Oncology during the 1st quarter valued at approximately $79,000. State of Wyoming bought a new position in shares of Kura Oncology during the 1st quarter valued at approximately $48,000. Trexquant Investment LP increased its position in shares of Kura Oncology by 21.0% during the 1st quarter. Trexquant Investment LP now owns 685,970 shares of the company’s stock valued at $4,527,000 after purchasing an additional 119,025 shares during the last quarter. Ieq Capital LLC bought a new position in shares of Kura Oncology during the 1st quarter valued at approximately $646,000. Finally, AlphaQuest LLC increased its position in shares of Kura Oncology by 189.1% during the 1st quarter. AlphaQuest LLC now owns 58,772 shares of the company’s stock valued at $388,000 after purchasing an additional 38,441 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently weighed in on KURA. Mizuho cut their target price on Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, May 19th. JMP Securities cut their price objective on Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating on the stock in a research report on Monday, August 11th. Wall Street Zen raised Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research note on Friday, June 20th. Finally, Barclays decreased their price target on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.10.

Kura Oncology Price Performance

KURA opened at $7.90 on Friday. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $21.57. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $6.43 and its 200-day simple moving average is $6.58. The company has a market capitalization of $685.72 million, a price-to-earnings ratio of -3.50 and a beta of 0.41.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.